Get started
Author

M. Aldea

1914P Sex differences in the tolerability to novel targeted therapies: Insights from a French lung cancer data system
2025 · C. Parisi, A. Lolivier, et al. · Annals of Oncology · 2
1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
2024 · A. Di Federico, M.F. Chen, et al. · Annals of Oncology · 2
PDF
425P: Real-world data of everolimus in patients with thymic epithelial tumors (TETs)
2025 · Á. López Gutiérrez, J.D. Florez Arango, et al. · Journal of Thoracic Oncology · 1
PDF
P4.11E.17 Clinical Outcomes and Immunotherapy Retreatment in Patients with Metastatic NSCLC Who Complete at Least Two Years of Immune Checkpoint Blockade
2024 · B. Ricciuti, L. Hong, et al. · Journal of Thoracic Oncology · 1
PDF
1070P Previous viral infections assessed by pan-virus phage immunoprecipitation sequencing (PhIP-Seq) predict response to immune checkpoint blockers (ICBs) in non-small cell lung cancer (NSCLC)
2022 · F.G. Dall'Olio, M. Lerousseau, et al. · Annals of Oncology · 1
Abstract PR005: KRAS amplification as de novo oncogenic alteration and therapeutic target in human cancers
2026 · Mark M. Awad, Biagio Ricciuti, et al. · Cancer Research
P4.17F.03 Utilizing AI for Automated Data Entry and Analysis to Pre-Screen Lung Cancer Clinical Trial Candidates
2024 · M. Aldea, P. Rolland, et al. · Journal of Thoracic Oncology
PDF
182P METHRO: Multicentric study of risk of thrombosis in patients with NSCLC harboring a METexon 14 skipping mutation
2024 · M.V. Sanchez Becerra, F. Pecci, et al. · ESMO Open
PDF
Works count: 8
Citation count: 7
H-index: 2
I10-index:
Year
Topic
Type